Grey Healthcare Adds Exubera Account
This article was originally published in The Pink Sheet Daily
Grey Healthcare Group will promote Pfizer/Sanofi-Aventis' inhaled insulin brand Exubera worldwide, GHG announced Sept. 23
You may also be interested in...
Change-in-control triggers discussion about future of Aventis partnerships. Sanofi notes that there is a defined timeline for negotiations, but the company is not making any details public.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.